This study will be conducted using 3+3 design and includes, a dose escalation part to define
the MTDfRP2D for the combination of BGJ398 and carboplatin/paclitaxel, and a dose expansion
part to treat another 12 patients (only cervix cancer) to further evaluate safety of this
combination. Safety, tolerability and MTD will be determined in the dose escalation part of
the study. The dose expansion will additionally investigate preliminary anti-tumor efficacy
in cervical cancer. The dosing cycle is 21 days.
Phase:
Phase 1
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio